
A fledgling transpacific biotech grabs a launch round to dive into oncology and autoimmune research
Precision-med biotech Allorion Therapeutics is expanding — and now has tens of millions of dollars more to work with.
The Natick, MA-based company announced in a statement this morning that it closed a Series A round, bringing in $40 million. Shanghai VC Qiming Venture Partners led the round, which also includes a number of both new and old investors — Octagon Capital, IDG Capital and TF Capital, to name a few.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.